News
Barclays Downgrades Exelixis to Equal-Weight, Maintains Price Target to $25
11 Apr 24
News, Downgrades, Price Target, Analyst Ratings
What Analysts Are Saying About Exelixis Stock
10 Apr 24
Analyst Ratings
JMP Securities Reiterates Market Outperform on Exelixis, Maintains $27 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
23 Feb 24
Long Ideas, News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $28
7 Feb 24
News, Price Target, Analyst Ratings
Recap: Exelixis Q4 Earnings
6 Feb 24
Earnings
Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimate, Sales $479.65M Miss $484.88M Estimate
6 Feb 24
Earnings, News
Earnings Scheduled For February 6, 2024
6 Feb 24
Earnings
Earnings Preview For Exelixis
5 Feb 24
Earnings
Stifel Maintains Hold on Exelixis, Raises Price Target to $25
2 Feb 24
News, Price Target, Analyst Ratings
Breaking Down Exelixis: 7 Analysts Share Their Views
30 Jan 24
Analyst Ratings
Barclays Maintains Overweight on Exelixis, Raises Price Target to $25
30 Jan 24
News, Price Target, Analyst Ratings
Press releases
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
16 Apr 24
Press Releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
27 Feb 24
Press Releases
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
14 Feb 24
Biotech, Press Releases, General
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
6 Feb 24
Press Releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
1 Feb 24
Press Releases